- If a doctor recommended testosterone replacement therapy would you rather take a pill one or two times a day, daily gel, or SQ injection once a week?
I know posters are going to jump on this & say SQ injection once a week but I don't think its that easy. The thought of injections has a negative stigma by a lot of individuals & even SQ injections leave some bruising.
The defense of SQ injections is that it has better efficacy then gels or oral meds. The other positive is one & done for the week.
I think oral & SQ are better alternatives then gels but oral is an easier product to market.
The problem with GRPO is the fear of competition. If Apple launches a camera then potential buyers would give it serious consideration unlike the current competition.
Market down 250 & this closes in the positive. Hopefully that's a good sign for the stock headed to more reasonable levels. This is one of the most undervalued biotechs out there.
Past history shows that you need two things for a bear market. Recession & the Fed raising rates. I agree that we're not there yet so I'm hoping this is just a correction.
I usually have a pretty good feel for where the markets headed but I'm clueless. I guess the strong dollar & fear the Fed will raise rates has investors headed for the exits. Earning numbers have not been that bad for the qtrbut Investors are expecting lower guidance for 2015. Can biotechs avoid a downturn in other sectors. I thought lower oil was going to prevent a big sell off but that might be wrong.
Short sellers are covering their short without moving the shareprice. That's exactly what you would want to happen if you were a short.
Managements job is to also get the story across to analysts & institutional investors in addition to delivering on the science.
OMG, that is unreal. I can't believe they could file a Citizen's Petition after the court settlement. This company is cursed.
I agree, Adam Feuerstein already said he plans to write something tomorrow so expect an article from him & then a quick move lower.
I read his article. Pretty convincing argument against the technology. I just don't understand how they could even move it into Phase I if the data is so bad.
No, they will stop the slide by releasing a PR on a new patent, or the hiring of another VP, or an undisclosed product with an undisclosed timeline.
can below $50. Doesn't quite make sense to let it trade at these levels.
William Lis sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $27.32, for a total transaction of $546,400.00.
Generic could have gained approval.